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Abstract
Background: Osteoarthritis (OA) is a common progressive joint disease in dogs and cats. The goal of OA treatment
is to reduce inflammation, minimize pain, and maintain joint function. Currently, non-steroidal anti-inflammatory
drugs (e.g., meloxicam) are the cornerstone of treatment for OA pain, but side effects with long-term use pose
important challenges to veterinary practitioners when dealing with OA pain. Palmitoylethanolamide (PEA) is a
naturally-occurring fatty acid amide, locally produced on demand by tissues in response to stress. PEA endogenous
levels change during inflammatory and painful conditions, including OA, i.e., they are typically increased during acute
conditions and decreased in chronic inflammation. Systemic treatment with PEA has anti-inflammatory and
pain-relieving effects in several disorders, yet data are lacking in OA. Here we tested a new composite, i.e.,
PEA co-ultramicronized with the natural antioxidant quercetin (PEA-Q), administered orally in two different rat
models of inflammatory and OA pain, namely carrageenan paw oedema and sodium monoiodoacetate (MIA)-induced
OA. Oral treatment with meloxicam was used as benchmark.
Results: PEA-Q decreased inflammatory and hyperalgesic responses induced by carrageenan injection, as shown by: (i)
paw oedema reduction, (ii) decreased severity in histological inflammatory score, (iii) reduced activity of myeloperoxidase,
i.e., a marker of inflammatory cell infiltration, and (iv) decreased thermal hyperalgesia. Overall PEA-Q showed
superior effects compared to meloxicam. In MIA-treated animals, PEA-Q exerted the following effects: (i) reduced
mechanical allodynia and improved locomotor function, (ii) protected cartilage against MIA-induced histological
damage, and (iii) counteracted the increased serum concentration of tumor necrosis factor alpha, interleukin 1
beta, metalloproteases 1, 3, 9 and nerve growth factor. The magnitude of these effects was comparable to, or
even greater than, those of meloxicam.
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Conclusion: The present findings shed new light on some of the inflammatory and nociceptive pathways and
mediators targeted by PEA-Q and confirm its anti-inflammatory and pain-relieving effects in rodent OA pain
models. The translatability of these observations to canine and feline OA pain is currently under investigation.
Keywords: Osteoarthritis, Disease models, Pain, Inflammation, Drug combinations, Palmitoylethanolamide, Quercetin,
Co-ultra micronization, N-acylethanolamines
Background
Osteoarthritis (OA) represents one of the most frequently
occurring painful conditions in both humans and small
animals [1]. In dogs, it affects approximately 20% of those
over the age of 1 year [2]. OA is also very common in eld-
erly domesticated cats, its prevalence being greater than
50% [3]. Clinical signs (i.e., lameness, stiffness, behavioral
and lifestyle changes) are largely related to persistent and
chronic pain [1–3], i.e. a mixed phenomenon involving
both inflammatory and neuropathic mechanisms at
the peripheral (joint) and central (spinal and suprasp-
inal) levels [4]. Currently, the most frequently used
analgesics for canine and feline OA are non-steroidal
anti-inflammatory drugs (NSAIDs) [4]. Despite their
widespread use, the main drawbacks of NSAIDs relate
to both poor efficacy against the neuropathic component
of OA pain [5] and unwanted side effects, especially with
long-term use [6]. Thus, research is now focused on the
identification of more effective and safe analgesic tools, as
part of an ideal multimodal management of pain in
veterinary OA patients [4, 7].
Given the aetiological and clinical heterogeneity of
canine and feline OA, several animal models have been
employed to investigate the multifaceted mechanisms of
OA pain and to evaluate the analgesic efficacy of differ-
ent compounds [8, 9]. Experimental OA pain models
that provide ease of induction and reproducibility with-
out the need for surgery are favored [9]. Of these, sub-
plantar carrageenan (CAR) injection is recognized as a
model of acute and highly reproducible inflammatory
pain [10, 11], the main signs of inflammation - oedema,
hyperalgesia, and erythema – developing immediately
following subcutaneous injection. Neutrophils readily
migrate to sites of CAR-induced inflammation and gen-
erate pro-inflammatory mediators, such as bradykinin,
histamine, and reactive oxygen and nitrogen species,
with consequent sensitization of local nociceptors and
inflammatory pain development [11]. Recently, the
intra-articular injection of sodium monoiodoacetate
(MIA) has been suggested to be more predictive of OA
pain drug efficacy than other models [8, 9]. MIA
inhibits a key glycolytic enzyme, leading to chondrocyte
cell death and bone lesions [9]. Pain-related character-
istics in the MIA model are considered to originate
from an inflammatory pain state induced by the local
increase of inflammatory cytokines, followed by gradual
initiation of neuronal cell injury and nerve sensitization,
culminating in neuropathic pain [9, 12].
Palmitoylethanolamide (PEA) is a naturally-occurring
N-acylethanolamine and a congener of the endocannabi-
noid anandamide [13]. First discovered in the 1950s as
the active anti-inflammatory component of some food
sources (recently reviewed in [14]), PEA has emerged as
a disease-modifying agent in conditions eliciting both
inflammatory and neuropathic pain, both in experimental
(e.g. intraplantar injection of formalin, chronic constric-
tion injury, viscerovisceral hyperalgesia) and naturally
occurring conditions (eg. diabetic neuropathy, low back
pain and pelvic pain in human patients) [13–15]. More-
over, PEA is currently considered a negative regulator of
tissue inflammation [14, 16]. However, its effect on joint
disease-related pain remains to be fully investigated. Avail-
able data are mainly limited to changes in endogenous
levels of PEA, with an increase being reported in the
spinal cord of MIA-treated rats [17] and a marked
decrease in the synovial fluid of human patients with OA
or rheumatoid arthritis [18]. These findings posit that
PEA metabolism is deregulated during joint disorders and
that exogenous supply of PEA may be beneficial in such
conditions [19].
Oxidative stress is considered to be an important
etiologic factor in OA [20], and the antioxidant quercetin
has been used with success as an adjunct in human and ex-
perimental arthritic diseases [21, 22]. New formulations of
PEA have recently been introduced in the Italian and inter-
national health market, both in the human and veterinary
fields [14]. These mainly comprise micronized or ultrami-
cronized formulations of PEA (i.e., micron- or submicron-
sized particles with better solubility), that show superior
activity compared to naïve PEA [23]. In some formulations,
PEA is micronized (or ultramicronized) together with
natural polyphenols, showing a synergistic effect and the
ability to target also the oxidative stress cascade [14]. The
newest of these formulations is a co-ultramicronized com-
posite of PEA with quercetin (PEA-Q).
Based on the above considerations, the present study
aimed to investigate the anti-inflammatory and pain-
relieving effects of PEA-Q. Two sets of experiments
were carried out. In the first (preliminary study) the
CAR-induced inflammatory rat pain model was used.
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The encouraging results thus obtained led us to then test
PEA-Q in the MIA-induced rat OA pain model. In both
sets of experiments pain thresholds were evaluated and in-
flammatory/nociceptive markers measured. In all these
studies meloxicam was used as a representative NSAID
commonly prescribed in Europe for treating chronic OA
pain in dogs and cats.
Methods
Animals
This study was performed on Sprague–Dawley male rats
(200–230 g, 7 weeks old, Envigo RMS Srl, S. Pietro al
Natisone, Udine, Italy). Ten rats were used for each
treatment group (see below). Food and water were avail-
able ad libitum. The University of Messina Review Board
for the care and use of animals authorized the study.
Animal care was in accordance with Italian regulations
on protection of animals used for experimental and
other scientific purposes (D.M.116192) as well as with
EEC regulations (O.J. of E.C. L 358/1 12/18/1986).
Reagents
Co-ultramicronized PEA-Q was kindly provided by
Epitech group SpA (Saccolongo, Italy). PEA-Q is the
result of the joint ultramicronization - by jet-milling
technology - of a mixture made of PEA and quercetin
in a 5:1 ratio by mass. All other compounds were ob-
tained from Sigma-Aldrich, Milan, Italy. All chemicals
were of the highest commercial grade available. All
stock solutions were prepared in non-pyrogenic saline
(0.9% NaCl, Baxter International, Rome, Italy).
Experimental models
CAR-induced inflammation
Rats were anesthetized with 5.0% isoflurane in 100% O2
(Baxter International, Rome, Italy) and received a sub-
plantar injection of CAR (0.1 ml/rat of a 1% suspension
in saline) (Sigma–Aldrich, Milan, Italy) as previously
reported [11]. Injections were performed using a 27-gauge
needle inserted into the pad region of the glabrous skin on
the underside of the right hind paw. At 6 h following CAR
injection, rats were sacrificed by anaesthetic (isoflurane)
overdose.
All analyses conducted in CAR-injected rats (see
details below) were performed in a blinded manner.
MIA induction model
OA was induced by intra-articular injection of MIA in
the right knee joint as previously described [24]. On day
0, rats were anesthetized with 5.0% isoflurane in 100%
O2. A volume of 25 μl saline +3 mg of MIA was injected
into the knee joint through the right intrapatellar liga-
ment. The left knee received an equal volume of saline.
MIA was prepared in sterile conditions and injected
using a 50 μl Hamilton syringe with a 27 gauge needle
that was inserted into the joint for about 2–3 mm. On
day 21 post-MIA injection, rats were sacrificed by anaes-
thetic overdose and perfused with 4% paraformaldehyde.
All analyses conducted in MIA-injected rats (see details
below) were performed in a blinded manner.
Experimental design
Treatment groups
The experiment was divided in two steps. First, we
conducted a preliminary study to evaluate the effect
of PEA-Q on inflammation and pain-related events
(i.e., thermal hyperalgesia) in the CAR-induced paw
oedema model. Rats were arbitrarily allocated to the
following treatment groups, each compound being
administered orally 30 min before CAR injection:
(i) CAR + vehicle (saline): rats were subjected to
CAR-induced paw oedema, as described above
(N = 10);
(ii) CAR + quercetin: same as the CAR + vehicle group
plus 3.3 mg/kg quercetin dissolved in
carboxymethylcellulose (1.5% w/v in saline)
(N = 10);
(iii)CAR + PEA-Q (10): same as the CAR + vehicle
group plus 10 mg/kg PEA-Q dissolved in
carboxymethylcellulose (1.5% w/v in saline)
(N = 10);
(iv)CAR + PEA-Q (20): same as the CAR + vehicle
group plus 20 mg/kg PEA-Q dissolved in
carboxymethylcellulose (1.5% w/v in saline)
(N = 10);
(v) CAR + meloxicam: same as the CAR + vehicle
group plus 0.2 mg/kg meloxicam dissolved in saline
(N = 10).
(vi) sham group: same surgical procedure as the CAR
group, except that saline was administered instead
of CAR (N = 10).
Doses were chosen based on a dose-response studied
carried out in our lab and on existing literature data.
The dose of quercetin used is equivalent to 20 mg/kg
PEA-Q. Based on preliminary results, we evaluated the
anti-inflammatory and analgesic effects of PEA-Q in an
experimental model of MIA-induced OA pain (definitive
study). Rats were randomly divided into the following
treatment groups, each compound being administered
orally three times per week for 21 days, starting the third
day after MIA injection:
(i) MIA + vehicle (saline): rats were subjected to
induction of OA pain as described above
(N = 10).
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(ii) MIA + PEA-Q (10): same as the MIA + vehicle
group plus 10 mg/kg PEA-Q dissolved in
carboxymethylcellulose (1.5% w/v in saline) (N = 10);
(iii)MIA + PEA-Q (20): same as the MIA + vehicle
group plus 20 mg/kg PEA-Q dissolved in
carboxymethylcellulose (1.5% w/v in saline) (N = 10);
(iv)MIA + meloxicam: same as the MIA + vehicle
group plus 0.2 mg/kg meloxicam dissolved in
carboxymethylcellulose (1.5% w/v in saline)
(N = 10);
(v) sham-operated group: rats received an
intra-articular injection of saline (25 μl) instead of
MIA (N = 10).
Quercetin was not tested in this set of experiments,
given the lack of effect observed in the previous set.
Doses were chosen based on a dose-response study
carried out in our lab and on existing literature data.
The timing of oral administration was based on a previ-
ous study [25].
The effect of PEA alone was not investigated, since
oral administration of micronized and ultramicronized
PEA had been shown to reduce inflammation and pain
in several experimental models, the effective dose being
10 mg/kg [13, 14], thus higher than the dose equivalent
to 10 mg/kg PEA-Q used here. Moreover, oral adminis-
tration of naïve PEA (non-micronized) did not exert any
significant effect against inflammation and hyperalgesia
up to 10 mg/kg [23].
Assessment of CAR-induced paw oedema
Oedma was assessed by directly measuring changes in
paw volume using a plethysmometer (Ugo Basile, Varese,
Italy), as previously described [11]. Paw volume was
measured immediately prior to CAR injection and there-
after at hourly intervals for 6 h. Oedema was expressed
as the increase in paw volume (ml) after CAR injection
relative to pre-injection value. Six hours after CAR injec-
tion, percentage inhibition (protection) against oedema
formation was calculated as follows and taken as an
index of anti-inflammatory activity:
Percentage inhibition of inflammation= [(Vc-Vt)/Vc] × 100,
where;
Vc = mean paw oedema volume in the control group
at 6 h;
Vt = mean paw oedema volume in the drug-treated
group at 6 h.
Pain-related behavioral analysis in the CAR model
The hyperalgesic response to heat was measured at
different time points (0, 30 min, 1, 2, 3, 4 and 5 h) based
on the method described by Hargreaves et al. [26] using
Plantar Test 7371 (Ugo Basile, Italy). Briefly, animals
were allowed to move freely within an open-topped
transparent plastic chamber. After an acclimation period,
a mobile infrared (I.R.) radiant heating source (IR 60) was
placed under the glass floor and focused onto the hind
paw. When the animal felt pain and withdrew its paw, the
I.R. source switched off and the reaction time counter
stopped. The withdrawal latency to the nearest 0.1 s was
then automatically determined and recorded. A cutoff
time of 20 s was set, i.e., if the rat failed to respond by 20 s
the test was stopped in order to prevent tissue damage in
non-responsive animals. Each point represents the delta
change (sec) in withdrawal latency (withdrawal latency of
contralateral minus withdrawal latency of injected paw) at
each time point. Results are expressed as paw withdrawal
latency changes (sec).
Percentage anti-hyperalgesic activity 5 h after CAR
injection was calculated as follows.
Percentage anti-hyperalgesic activity = [(Vt-Vc)/Vt] × 100
where:
Vc = mean paw withdrawal latency in the control
group at 5 h;
Vt = mean paw withdrawal latency in the drug-treated
group at 5 h.
Histological analysis following CAR injection
Six hours after intraplantar CAR injection, animals were
terminally anesthetized and paw biopsies collected. Histo-
logical analysis of haematoxylin and eosin-stained paw
tissue was performed as previously described [23]. The de-
gree of paw damage was evaluated according to Bang and
Coll. [27], on a six-point score: 0 = no inflammation,
1 = mild inflammation, 2 = mild/moderate inflammation,
3 = moderate inflammation, 4 = moderate/severe inflam-
mation and 5 = severe inflammation. The photographs
obtained (n = 5 photos from five slides for each sample)
were collected from all animals in each experimental
group. The histological coloration (5 slides for each same
sample) was repeated three times on different days.
Myeloperoxidase (MPO) activity following CAR injection
MPO activity, an index of neutrophilic granulocyte infil-
tration, was evaluated as previously described [28]. Briefly,
after animals were terminally anesthetized paw tissues
were collected and homogenized in a solution containing
0.5% hexadecyltrimethylammoniumbromide dissolved in
10 mM potassium phosphate buffer (pH 7) and centri-
fuged for 30 min at 20000 g (4 °C). The supernatant
was allowed to react with a solution of tetramethylben-
zidine (1.6 mM) and 0.1 mM H2O2. The rate of change
in absorbance was measured spectrophotometrically at
650 nm. MPO activity was measured as the quantity of
enzyme degrading 1 mM of peroxide min−1 at 37 °C,
and expressed in units per gram of wet tissue weight.
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Assessment of MIA-induced mechanical allodynia
Mechanical allodynia was evaluated using a dynamic plan-
tar Von Frey hair aesthesiometer on day 0 and 3, 7, 14
and 21 days post-injection (Ugo Basile, Comerio, Italy).
Rats were located on a metal mesh surface in a chamber
in a room with controlled temperature (21-22o C) and
were allowed to adapt for 15 min before testing began.
The touch stimulator part was positioned under the rat.
When the aesthesiometer was activated, a plastic mono-
filament touched the paw in the metatarsal region. The
filament exercised a gradually increasing force on the
plantar surface, starting below the threshold of detection
and increasing until the stimulus became painful and the
rat removed its paw. The force required to produce a paw
withdrawal reflex was recorded automatically and mea-
sured in grams. A maximum force of 50 g and a ramp
speed of 20 s were used for all the aesthesiometry tests.
Paw withdrawal latency (PWL) and paw withdrawal
threshold (PWT) were calculated.
Motor function analysis (walking track analysis) following
MIA injection
Motor functional recovery of the rear limb was evaluated
by walking track analysis, a reliable and easily quantifiable
noninvasive method based on gait analysis by means of
specific footprint parameters [29]. In brief, rats were previ-
ously trained to walk down a track with a dark end,
covered with strips of white paper. Tracks were obtained
by wetting the rat’s hind feet with water soluble black ink.
Walking track analysis was performed in all animal groups
before MIA injection (day 0) and 3, 7, 14 and 21 days
post-injection. From the footprints, several measurements
are taken between different anatomic landmarks (e.g.,
width and length of the footprint) and then incorporated
in a mathematical formula, allowing the calculation of the
functionality index of the sciatic nerve (SFI), with values
close to 0 indicating normal function, and values tending
to −100 indicating total impairment [29].
Histological analysis of MIA-injected rats
On day 21 post-MIA injection, rats were sacrificed and
perfused with 4% paraformaldehyde. The MIA- and
vehicle-injected tibiofemoral joints were dissected and
post-fixed in neutral buffered formalin (containing 4%
formaldehyde), decalcified in EDTA and processed as
previously described. After decalcification, the specimens
were embedded in paraffin. Mid-coronal tissue sections
(5 μm) were stained for evaluation; all histomorpho-
metric analyses were performed by an observer blinded
to the treatment group. Sections were stained with
haematoxylin and eosin and observed by light micros-
copy (Dialux 22 Leitz; Leica Microsystems SpA, Milan,
Italy). Histopathological analysis of the cartilage was
assessed by the modified Mankin score [30]. Briefly, the
score assessed: (i) structure, (ii) cellular abnormalities, and
(iii) matrix staining of cartilage sections and ranged from
0 (= normal histology) to 12 (= complete disorganization
and hypocellularity). The photographs obtained (n = 5
photos from five slides for each sample) were collected
from all animals in each experimental group. The histo-
logical coloration (5 slides for each same sample) was
repeated three times on different days.
Serum concentration of inflammatory, nociceptive and
matrix degradation markers following MIA injection
The concentration of tumor necrosis factor alpha (TNF-α),
interleukin-1beta (IL-1β), nerve growth factor (NGF),
and matrix metalloproteinase-1-3-9 (MMP-1, MMP-3,
MMP-9) were measured in serum using commercial
colorimetric ELISA kits (TNF-α, IL-1β, NGF: Thermo
Fisher Scientific, DBA s.r.l. Milan Italy; MMP-1 MMP-3
MMP-9: Cusabio, DBA s.r.l. Milan Italy).
Data analysis
Data are expressed as mean ± standard error of the
mean (SEM) of N observations, N representing the num-
ber of animals analyzed, with the exception of the
ordinal level variable (i.e., histological score), for which
median and range were used. In experiments involving
histology, the figures are representative of at least three
experiments performed on different days. The response
over time was analyzed using a generalized linear mixed
model (GLMM) for repeated measures, followed by
Tukey-Kramer post-hoc analysis. One time evaluations
with continuous level data were analyzed using ANOVA
followed by Bonferroni-Holm post hoc analysis. Kruskal-
Wallis test followed by Dunn’s test for post-hoc compari-
sons with Bonferroni-Holm p correction was used for
the histological score, due the ordinal level nature of the
variable (i.e., 0 to 5 point scale). Data were analyzed
using SAS v9.2 (SAS Institute, Cary, NC, USA). The
significance threshold was set at 0.05. Exact p values
are reported, unless less than 1 out of 10,000 (reported
as p < 0.0001), 0.0001 being the lower limit for the stat-
istical program.
Results
Preliminary study
A. Effect of PEA-Q on the time-course of CAR-induced paw
oedema
Intraplantar injection of CAR in rats led to a significant
time-dependent increase in paw volume, reaching a peak
after 3 h (p < 0.0001) (Fig. 1a). Oral treatment with
PEA-Q at 10 mg/kg significantly reduced paw volume at
3, 4, 5 and 6 h after injection (p = 0.0007, p = 0.0005,
p = 0.0250 and p = 0.0029 respectively). The same
results were observed for 20 mg/kg (p < 0.0001 at all
time points) (Fig. 1a). Overall the effect of both doses of
Britti et al. BMC Veterinary Research  (2017) 13:229 Page 5 of 13
PEA-Q was longer compared to meloxicam, whose effect
was no more statistically significant at 6 h. No significant
difference was observed at any time points between the
two doses of PEA-Q or between either dose of PEA-Q
and meloxicam. Quercetin did not achieve a significant re-
duction at any of these time points (Fig. 1a). The percent-
age of anti-inflammatory activity of the tested compounds
(quercetin, 10 and 20 mg/kg PEA-Q, and meloxicam) was,
respectively, 10%, 30%, 45% and 12% (Fig. 2a).
B. Effect of PEA-Q on the time-course of CAR-induced
thermal hyperalgesia
Intraplantar injection of CAR led to a statistically signifi-
cant time-dependent development of thermal hyperalge-
sia, latency being increasingly decreased at 30 min, 1 h,
2 h and 4 h after injection (p = 0.0209, p < 0.0001,
p = 0.0004, p < 0.0001 respectively) (Fig. 1b). Oral treat-
ment with PEA-Q (10 and 20 mg/kg) was efficacious in
decreasing the hyperalgesic response from the first to
the fifth hour after injection (p < 0.0001 for both doses
and all time points) (Fig. 1b). Moreover, the higher dose of
PEA-Q resulted to be superior to the lower (p < 0.0001 at
all time points). Similarly to paw oedema, the effect of
meloxicam was shorter, statistical significance being lost at
the fifth hour. Limited to the first and the second hour
post-injection, the anti-hyperalgesic effect exerted by
10 mg/kg PEA-Q was significantly higher than that of
meloxicam (p = 0.0309 and p = 0.0230 respectively).
Superiority of 20 mg/kg PEA-Q over meloxicam was
maintained at all time points (p < 0.0001). Quercetin was
unable to change withdrawal latency (Fig. 1b). The per-
centage of anti-hyperalgesic activity of the tested com-
pounds ranged from 12% (quercetin) to 57% (20 mg/kg
PEA-Q) (Fig. 2b).
C. Effect of PEA-Q on CAR-induced histological damage
Sham rats exhibited no histological damage (Fig. 3a and
inset a1). In contrast, CAR paw injection led to a
marked infiltration of inflammatory cells (Fig. 3b and
inset b1). Clear improvements were seen in paw tissues
Fig. 1 Effects of PEA-Q on CAR-induced paw oedema and heat hyperalgesia. Paw oedema and hyperalgesia were measured at the time points
indicated. Oral treatment with PEA-Q (10 and 20 mg/kg) produced a significant improvement in paw volume that, unlike meloxicam, lasted
up to the latest time point (a). In addition, PEA-Q was more effective in decreasing the hyperalgesia compared meloxicam (b). See Methods
for further details. Values are means ± SEM of 10 animals for each group. *p < 0.05, **p < 0.001 and ***p < 0.0001 vs previous time point. #p < 0.05,
##p < 0.001, ###p < 0.0001 vs CAR + vehicle. °p < 0.05 and °°°p < 0.0001 vs CAR + meloxicam. The exact p values are reported in the text
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of rats treated with PEA-Q at both doses (Fig. 3 d, d1; e,
e1), while little effect was observed in the quercetin- and
meloxicam-treated groups (Fig. 3c, c1, and Fig. 3f, f1).
Histological score in the vehicle group (median 4, range
4–5) was significantly improved by PEA-Q both at
10 mg/kg (median 2, range 2–3) and 20 mg/kg dose
(median 1, range 1–2) (p < 0.0001 for both doses). Quer-
cetin (median 4, range 3–4) and meloxicam (median 3,
range 3–4) did not significantly change the severity of
the histological score compared to vehicle (Fig. 3g).
D. Effect of PEA-Q on CAR-induced increase in MPO activity
The development of histological damage was associated
with a statistically significant increase in MPO activity
(p < 0.0001), a marker of neutrophilic infiltration (Fig. 3h).
Treatment with PEA-Q (p < 0.0001, both doses) and
meloxicam (p = 0.0014), but not quercetin, significantly re-
duced MPO activity compared to vehicle (Fig. 3h). PEA-Q
at the higher dose showed a statistically significant higher
effect compared to meloxicam (p = 0.0051).
Definitive study
A. Effect of PEA-Q on pain and motor function deficits
following MIA induction
Because pain is the hallmark of MIA-induced OA, mech-
anical allodynia in MIA-injected rats was assessed. In the
von Frey hair assessment test, PWT (Fig. 4a) and PWL
(Fig. 4b) were significantly decreased in the MIA + vehicle
group compared to sham animals (p < 0.0001 for both var-
iables at any time point). Treatment with PEA-Q at both
doses (p < 0.0001 at any time point and either dose) and
meloxicam (p = 0.0103 day 3 and p < 0.0001 at the follow-
ing time points) significantly prolonged PWTcompared to
the MIA + vehicle group at different time points (Fig. 4a).
Similar findings were obtained on PWL (p < 0.0001 at
all time points for any treatment), with the only
difference that the effect of the lower dose of PEA-Q
became significant at the seventh day (p < 0.0001 at 7,
14 and 21 days post-injection, Fig. 4b). The sham group
showed no evident time-dependent changes (Fig. 4a, b).
PEA-Q at 20 mg/kg dose resulted to exert a superior ef-
fect on both PWT and PWL compared to the lower dose
and to meloxicam (p < 0.0001 for both variables and
both comparisons, at any time point) (Fig. 4a, b).
Furthermore, rats treated with PEA-Q at 20 mg/kg ex-
hibited nociceptive behaviors that were not statistically
different from the sham group up to day 14 and 21 for
PWT and PWL respectively. In addition, motor function
at different time points was assessed by walking track
analysis. The sham group showed normal motor activity,
with SFI approximating 0. In the MIA + vehicle group,
SFI values were significantly lower than in sham animals,
locomotor function being increasingly impaired at 3, 7,
14 and 21 days (Fig. 4c) (p < 0.0001 at all time points).
Treatment with both PEA-Q and meloxicam signifi-
cantly improved locomotor function at both 14 and
21 days (p < 0.0001 for each treatment and either time
points) with no statistically significant differences being
observed among treatments (Fig. 4c).
B. Effect of PEA-Q on MIA-induced histopathological
changes
Histological examination of haematoxylin/eosin-stained
knee sections 21 days after intra-articular injection of
MIA showed a reduction in blood cells, irregularities in
the surface layer, and multi-layering in transition and ra-
dial zones of the cartilage compared to sham (Fig. 5a, b
see Mankin score F) (p < 0.0001). Treatment with PEA-
Q at both doses reduced the histological cartilage
changes induced by MIA injection (Fig. 5c,d see Mankin
score F) (p < 0.0001 for either doses), the higher dose
showing superior effect compared to the lower dose
Fig. 2 Effects of PEA-Q on CAR-induced inflammation and analgesic activity. Percentages of anti-inflammatory (a) and analgesic activity (b) for
the tested compounds as measured, respectively, at 6 h and 5 h post-CAR injection. See Methods for further details
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(p = 0.0058) and meloxicam (p = 0.0113, Fig. 5e see
Mankin score F).
C. Effects of PEA-Q on plasma concentration of inflammatory,
nociceptive and matrix degradation markers
A significant increase in serum concentration of the
pro-inflammatory cytokines TNF-α (p = 0.0047, Fig. 6a)
and IL-1β (p = 0.0007, Fig. 6b) and a similar increase in
the level of the nerve sensitizer NGF (p < 0.0001, Fig. 6c)
were observed in the MIA + vehicle group compared to
sham animals. Treatment with PEA-Q significantly coun-
teracted such increases at both 10 mg/kg (TNF-α,
p = 0.0003; IL-1β, p = 0.0029; NGF, p = 0.0226) and
20 mg/kg dose (TNF-α, p < 0.0001; IL-1β, p = 0.0001;
NGF, p = 0.0002). Similar findings were observed for
meloxicam (TNF-α, p < 0.0001; IL-1β, p < 0.0001; NGF,
p = 0.0017). Limited to TNF-α concentration, PEA-Q at
the higher dose sowed a superior effect compared to the
lower dose (p = 0.0070) and to meloxicam (p = 0.0443).
In addition, MIA + vehicle rats showed a markedly
higher expression of the matrix degradation enzymes
MMP-1 (Fig. 6d), MMP-3 (Fig. 6e), and MMP-9 (Fig. 6f )
compared to the sham group (p < 0.0001 for all the
three). PEA-Q significantly decreased MMP concentra-
tion compared to the vehicle-treated group, both at the
10 mg/kg dose (MMP-1, p = 0.0120; MMP-3,
p = 0.0032; MMP-9, p = 0.0142) and at the 20 mg/kg
one (MMP-1, p = 0.0002; MMP-3, p < 0.0001; MMP-9,
p = 0.0003), similar to that observed with meloxicam
(MMP-1, p = 0.0019; MMP-3, p = 0.0011; MMP-9,
Fig. 3 Effects of PEA-Q on CAR-induced histological damage and neutrophil infiltration. Histological evaluation was performed by haematoxylin
and eosin staining. Panels a-a1, sham; panels B-B1, CAR-injected; Panels c-c1, quercetin treatment; Panels d, d1 and e, e1, PEA-Q treatment;
Panels f, f1 meloxicam treatment. Figures are representative of all animals in each group. Panel g, histological score for the various treatment
groups. Distribution of data is represented by box plot analysis. Panel h, MPO activity. Values are means ± SEM of 10 animals for each group.
***p < 0.0001 vs sham. #p < 0.05 and ###p < 0.0001 vs CAR + vehicle. °p < 0.05 vs CAR + meloxicam. The exact p values are reported in the text
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p = 0.0044) (Fig. 6d–f ). No statistically significant differ-
ence was observed between different PEA-Q doses or
between either dose of PEA-Q and meloxicam.
Discussion
Here we show for the first time that a new co-
ultramicronized composite, made of the anandamide
congener PEA and the natural polyphenol quercetin
(PEA-Q), exerts beneficial effects in both inflamma-
tory and mixed persistent OA pain in rats. Although
the anti-inflammatory and anti-hyperalgesic activities
of PEA have been clearly demonstrated in several in-
flammatory and neuropathic pain models [13–15, 31],
reports on joint disease-related pain states are scarce,
with no study having yet been performed with PEA-
Q. Conceivably, PEA-Q could dissociate into its single
components (PEA and quercetin) after oral adminis-
tration, although there is evidence supporting the syn-
ergistic effect of PEA and polyphenols [32]. OA pain
is, without doubt, complex in its cellular/molecular
mechanisms. As such, designing therapeutics that provide
optimal efficacy may call for the use of models that allow
one to evaluate distinct features of the disease in the con-
text of the agent being evaluated. Indeed, we used both
the CAR paw oedema and MIA-induced OA models,
since previous studies gave information about the poten-
tial effect of the two components of PEA-Q on both
inflammatory and neuropathic pain.
Intraperitoneal administration of ultramicronized PEA,
alone or co-micronized with the polyphenol luteolin, is
able to restore normal pain sensitivity and decrease
inflammation in a rat model of rheumatoid arthritis [32].
In human patients, a two-week oral treatment with
micronized PEA showed superior activity compared to
the NSAID ibuprofen in decreasing temporomandibular
joint inflammatory pain and improving joint function
(better mandibular range of motion) [33]. Further,
pharmacological inhibition of PEA degradation (which
elevates tissue PEA levels), results in anti-hyperalgesic ef-
fects in arthritic pain models [34–36]. The pain relieving
activity observed for PEA-Q is in line with these earlier
findings, although direct comparisons are difficult due to
different models and PEA formulations employed.
Quercetin has been reported to exert pain-relieving
effects in different pain models [37] and, in particular,
is able to reduce: (i) CAR-induced mechanical hyper-
algesia [37], (ii) chemotherapy-induced neuropathic
pain [38], (iii) diabetic neuropathic pain [37], and (iv)
muscle mechanical hyperalgesia [39]. We were unable
to confirm these observations, since quercetin did not
show any significant effect on paw oedema or thermal
sensitivity in the CAR-induced inflammatory pain
model. This apparent lack of effect could result from
differences in dosage used: we tested quercetin at
3.3 mg/kg (equivalent to 20 mg/kg PEA-Q), while the
dosage used in the above-mentioned studies was approxi-
mately 100 mg/kg. Further synergistic studies will be
Fig. 4 Effects of PEA-Q on MIA-induced OA pain and motor function. Paw withdrawal threshold a, paw withdrawal latency b and motor function
c as recorded for each treatment group before and after 3, 7, 14 and 21 days from the intra-articular injection of MIA. Data are means ± SEM of 10 rats
for each group. ***p < 0.0001 versus sham. #p < 0.05 and ###p < 0.0001 vs MIA + vehicle. °°°p < 0.0001 vs MIA + PEA-Q (10 mg/kg) and
MIA + meloxicam. The exact p values are reported in the text
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Fig. 6 Effects of PEA-Q on MIA-induced plasma cytokines, metalloproteinases and NGF in OA rats. Increased TNF-α (a) IL-1β (b), NGF (c) and
MMP1 (d), MMP-3 (e), MMP-9 (f) plasma concentrations were detected in the MIA + vehicle group compared to sham animals. PEA-Q treatment sig-
nificantly reduced the plasma concentration of all measured parameters, with effects being comparable to the meloxicam group. Values are
means ± SEM of 10 animals for each group. *p < 0.05, **p < 0.001 and***p < 0.0001 vs sham. #p < 0.05, ##p < 0.001 and ###p < 0.0001 vs
MIA + vehicle. °p < 0.05 vs MIA + PEA-Q (10 mg/kg) and MIA + meloxicam. The exact p values are reported in the text
Fig. 5 Effects of PEA-Q on MIA-induced histological features of OA knee tissue. Histological evaluation was performed by haematoxylin and eosin
staining. Panel (a), sham; panel (b), MIA–injected; Panels (c) and (d), PEA-Q treatment; Panels d and (e), meloxicam treatment. Figures are
representative of all animals in each group. Panel (f), Mankin score for the various treatment groups. Values are means ± SEM of 10 animals for each
group. ***p < 0.0001 vs sham. ###p < 0.0001 vs MIA + vehicle. °p < 0.05 vs MIA + PEA-Q (10 mg/kg) and MIA + meloxicam
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needed to better characterize the contribution of
quercetin to the activity of PEA-Q.
It was somewhat surprising that meloxicam exerted an
anti-allodynic effect in the MIA model (significant
improvement of PWL and PWT). NSAIDs are usually
considered to be ineffective on allodynia, as recently
shown in naturally-occurring OA in cats subjected to
punctuate tactile allodynia quantification [40]. Again,
differences in dosages used in the former study and ours,
as well as species differences and nature of the disease
(spontaneous versus chemically-induced OA) could be
responsible for the apparent discrepancy. Although allo-
dynia might not be the main target of meloxicam, its
ability to improve functional parameters and pain scores
in dogs with joint pain has been repeatedly demon-
strated [41, 42]. Our findings on improved mechanical
sensitivity and motor function following meloxicam are
in line with the above-cited studies. PEA-Q also signifi-
cantly improved locomotor function, as measured by
walking track analysis. Interestingly, this analysis com-
bines gait with the temporal and spatial relationship of
one footprint to another during walking [29]. MIA injec-
tion is known to cause dropping of the foot to the ground,
resulting in visible footprint changes [29]. One can envis-
age that these changes are associated with enhanced noci-
ception and “antalgic gait”. That is to say, OA animals
minimize contact with the floor during walking. This
could well correlate with the situation of OA dogs, in
which walking likely causes enhanced nociception in the
affected limb(s) leading to lameness. The decrease of walk-
ing alterations observed in our study might thus be clinic-
ally relevant and can be considered a measure of the
motor functional recovery exerted by PEA-Q, as well as
meloxicam.
The ability to decrease not only pain and locomotor
deficits, but also inflammation is a further point in favor
of the therapeutic use of PEA-Q in animals affected with
OA. Inflammation and related soluble mediators are
involved in: (i) the generation of acute pain, (ii) the
vicious cycle of pain maintenance and chronicity, and
(iii) the predominance of catabolic processes over ana-
bolic ones, ultimately resulting in tissue degradation and
damage at the cartilage and bone levels [7]. PEA-Q sig-
nificantly reduced inflammatory paw oedema, and is in
accordance with data obtained in the same model using
either PEA [23, 43, 44], or PEA co-ultramicronized with
various polyphenols [45]. Interestingly, PEA-Q showed a
longer anti-inflammatory effect compared to meloxicam,
whose effect lost significance at an earlier time point.
Neither meloxicam nor quercetin achieved statistical
significance in decreasing histological signs of inflamma-
tion, while oral treatment with PEA-Q resulted in a clear
reduction in histological inflammatory score. The effect
was paralleled by a significant reduction in MPO activity
(the most abundant pro-inflammatory enzyme of neutro-
philic granulocytes) in PEA-Q treated rats, which proved
to be superior to meloxicam in reducing neutrophil in-
filtration in paw tissues. These results are in agreement
with previous studies, showing that PEA decreased in-
flammatory cell infiltration in different inflammatory
models [23, 46, 47]. Notably, the increase of pro-
inflammatory, nociceptive and proteolytic markers ana-
lyzed was significantly counteracted by PEA-Q to the
same extent (and even better concerning TNF-α) as
with meloxicam. Interestingly, cytokines (e.g., IL-1β,
TNF-α) and MMPs are considered to play a crucial role
in chondrocyte cell death and matrix degeneration [7, 48]
and NGF is currently viewed as a key regulator of nocicep-
tive and neuropathic pain [49]. Given that (i) the concen-
tration of NGF in canine synovial fluid is significantly
increased in chronically lame dogs [50], and (ii) feline
OA-associated pain improves under treatment with a
anti-NGF antibody [51], the ability of PEA-Q to reduce
NGF levels during experimentally-induced OA holds
promise for a disease-modifying effect against pain in
canine and feline OA patients.
PEA-Q counteracted histological OA changes caused
by MIA injection in the tibiofemoral joint and signifi-
cantly decreased the severity of cartilage degeneration,
the effect being superior to meloxicam. To the best of
our knowledge no study has investigated the effect of
either PEA or quercetin on histological joint damage,
and so it is difficult to compare our data with previous
findings. The only available data in this regard involves
the effectiveness of intra-articular injected meloxicam,
which decreased joint histologic score in MIA rats - al-
beit without reaching statistical significance [52].
Although complete extrapolation of efficacy from the
pre-clinical models used here to veterinary patients
would be unadvised, the present findings shed new light
on some of the inflammatory and nociceptive pathways
and molecules targeted by PEA-Q. In the present study,
the use of two different models and assessment of the
effect at different levels (behavioural, tissue, and molecu-
lar) to a large extent address the most relevant ques-
tions. Moreover, the pain-relieving effect of PEA-Q not
only on CAR-inflammation but also on MIA-related
pain supports its use in OA pain states, where inflamma-
tory and neuropathic mechanisms frequently coexist.
Studies on the effects of PEA-Q on pain and locomotion
in lame dogs are in progress.
Conclusions
PEA-Q is a novel co-ultramicronized formulation of
PEA and quercetin whose effects were investigated in
two pre-clinical models of OA pain in rats. Oral admin-
istration of PEA-Q decreased pain sensitivity, improved
locomotor function, reduced inflammatory signs and
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mediators and lowered histological damage score.
Although the underlying mechanism(s) of the observed
effects are beyond the scope of our study, the particular
cellular targets of PEA (e.g., mast cells and microglia)
[19], redundancy of its receptors (direct and direct
agonism on nuclear and membrane cannabinoid recep-
tors) [14] and oxidative stress addressed by quercetin
[22, 37] comprise targets that could be different from
standard pharmacological tools (i.e., NSAIDs). Import-
antly, toxicological studies show that micronized and
ultramicronized PEA is safe, the LD50 being greater
than 2000 mg/kg [53]. Individually or in association
with different antioxidant polyphenols, micronized and
ultramicronized PEA has a long track record of use in
human and veterinary patients, with good-to-excellent tol-
erability [14]. Moreover, prolonged use of PEA is not asso-
ciated with the development of tolerance [43, 54]. There is
an unmet need in veterinary medicine for the develop-
ment of new agents to treat OA-associated pain which
target alternative mechanisms distinct from currently ap-
proved drugs. The collective observations presented here
propose that PEA-Q shows promise for multimodal pain
management in canine and feline OA.
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